Empaveli
| Chemical Name | pegcetacoplan |
| Dosage Form | Injection (subcutaneous; 1,080 mg/20 mL (54 mg/mL)) |
| Drug Class | Complement inhibitors |
| System | Multiple |
| Company | Apellis Pharmaceuticals |
| Approval Year | 2021 |
Indication
- For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).